Circio Holding

Mindre end 1K følgere

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Markedsværdi

-

Aktieomsætning

-

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

8.5

2026

Generalforsamling '26

31.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelsefor 22 timer siden

Circio Holding ASA: Cancellation of Subsequent Offering

Selskabsmeddelelse17.4.2026, 12.15

Circio Holding ASA – Notice of annual general meeting 2026

Selskabsmeddelelse16.4.2026, 05.00

Mandatory adjustment of RSUs and share options following recently completed rights issue

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse15.4.2026, 17.47

Circio Holding ASA: Annual Report and Remuneration Report for 2025

Selskabsmeddelelse15.4.2026, 05.00

CRNA: Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

Pressemeddelelse15.4.2026, 05.00

Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

Selskabsmeddelelse14.4.2026, 09.24

Circio Holding ASA: Registration of share capital increase following private placement of approximately NOK 250 million

Selskabsmeddelelse8.4.2026, 05.00

Circio Holding ASA: Ex. right to participate in potential subsequent offering today

Selskabsmeddelelse8.4.2026, 05.00

Circio Holding ASA: Ex. right to participate in potential subsequent offering today

Selskabsmeddelelse8.4.2026, 00.59

Circio Holding ASA: Key information relating to potential subsequent offering

Selskabsmeddelelse8.4.2026, 00.42

Circio announces that it has completed a significantly oversubscribed financing of NOK 250 million

Selskabsmeddelelse8.4.2026, 00.06

Circio Holding ASA – Key events and financial highlights – 2H 2025 and YTD 2026

Pressemeddelelse26.3.2026, 12.40

Circio enters in vivo cell therapy collaboration with United Immunity

Selskabsmeddelelse18.3.2026, 13.45

Circio selected for oral presentation at prestigious ASGCT annual meeting

Selskabsmeddelelse26.2.2026, 06.00

Circio presents groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye

Selskabsmeddelelse19.2.2026, 06.00

Circio invites to R&D and corporate update webcast on 26 February 2026

Selskabsmeddelelse17.2.2026, 09.33

Circio Holding ASA: Registration of share capital increase following directed issue of NOK 3.6 million

Selskabsmeddelelse16.2.2026, 06.00

CIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING

Selskabsmeddelelse14.2.2026, 08.57

Circio announces allocation of stock options to key employees

Selskabsmeddelelse12.2.2026, 22.12

CRNA: Financial calendar

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.